.After raising $170 million back in February, metabolic disease-focused BioAge Labs has filed to debut on the general public market.The Eli Lilly-partnered biotech hopes to note on the Nasdaq under the symbol "BIOA," depending on to records filed along with the Stocks and Exchange Payment. The firm has actually not openly shared an anticipated monetary volume for the offering.The clinical-stage business promotes lead candidate azelaprag, a by mouth provided little particle slated to get into period 2 screening in combination with semaglutide-- marketed through Novo Nordisk under trademark name Wegovy for weight loss-- in the 1st fifty percent of upcoming year. Semaglutide is actually likewise sold as Ozempic and also Rybelsus by Novo for diabetes.
Apelin receptor agonist azelaprag is developed to combine effectively along with GLP-1 drugs, increasing fat loss while preserving muscular tissue mass. The investigational medicine was actually found to become well-tolerated among 265 people all over 8 stage 1 trials, according to BioAge.Formerly, BioAge achieved the assistance of Lilly to operate a test mixing azelaprag with the Major Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is actually industried for diabetic issues as Mounjaro and also Zepbound for weight reduction. The partners are actually currently conducting a period 2 trial of azelaprag and tirzepatide, with topline outcomes anticipated in the 3rd quarter of 2025.The biotech is likewise intending a blood insulin sensitivity proof-of-concept test determining azelaprag as a monotherapy in the initial fifty percent of following year to support potential sign growth. On top of that, the firm organizes to talk to the FDA for authorization in the second one-half of 2025 to release human screening for an NLRP3 inhibitor targeting metabolic conditions and also neuroinflammation.BioAge's foreseed transfer to everyone market complies with a light uptick in organized biotech IPOs from Bicara Rehabs and also Zenas Biopharma. Zooming out, the current IPO garden is a "combined picture," along with premium business still debuting on the general public markets, only in reduced numbers, according to PitchBook.